GlobeNewswire

Arcadis reports transactions under its current share buyback program

Share

Amsterdam, July2, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 87,964 of its own shares in the period from 25 June up to and including 1 July 2021 at an average price of €35.27. The consideration of this repurchase was €3.1 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021.

The total number of shares repurchased under this program to date is 1.4 million shares for a total consideration of €47.7 million.

For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/

-End-

Improving quality of life

FOR FURTHER INFORMATION PLEASE CONTACT:

ARCADIS INVESTOR RELATIONS
Jurgen Pullens
Mobile: +31 6 51599483
E-mail: jurgen.pullens@arcadis.com

ABOUT ARCADIS
Arcadis is the leading global design & consultancy organization for natural and built assets. We maximize impact for our clients and the communities they serve by providing effective solutions through sustainable outcomes, focus and scale, and digitalization. We are over 27,000 people, active in more than 70 countries that generate €3.3 billion in revenues. We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. www.arcadis.com

REGULATED INFORMATION
This press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Hexagon Digital Wave signs new equipment and service agreement with Linde29.7.2021 09:00:00 CEST | Press release

Hexagon Digital Wave, a business of Hexagon Composites has signed an agreement with Linde, a leading industrial gas and engineering company. The agreement covers the supply and service of Ultrasonic Examination (UE) testing equipment. The estimated total value of the agreement is USD 2 million (approx. NOK 17 million) and designates Hexagon Digital Wave as a long-term partner. Driving energy transformation “We are excited to extend our relationship with the great team at Linde”, says Keith Fountain, UE international Sales Manager Hexagon Digital Wave. “Over the past 14 years we have provided our equipment to one of the market leaders in the industrial gas environment and helped to improve the safety of their cylinders.” About the market The non-destructive UE test and process enables the recertification of the cylinders without removing the internal product which improves the safety and allows a number of ESG requirements to be accomplished. Positive environmental impacts are accomplis

Nexstim Receives an NBS System Order from a University Hospital in Germany29.7.2021 09:00:00 CEST | Press release

Press release, Helsinki, 29 July 2021 at 10 AM(EEST) Nexstim Receives an NBS System Order froma University Hospital in Germany Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received an NBS System order in Germany. The customer is a German university hospital and a new customer for Nexstim. Nexstim NBS systems with SmartFocus® nTMS technology are mainly used for neurosurgical diagnostics: One of the most crucial pieces of information needed for neurosurgery or radiotherapy is the tumor’s or other lesion’s location in relation to the essential functions and their connections in the patient’s brain. SmartFocus® nTMS mapping with Nexstim’s NBS system can give this information regarding motor and speech areas — it can be invaluable when deciding the best treatment option. Mikko Karvinen, CEO of Nexstim commented: “We are very happy about our continued success in expanding our NBS presence within the German university hospitals. This sale is a good start t

GeoJunxion NV (ticker: GOJXN.AS) Formerly called AND International Publishers NV (AND.AS) Publishes its July 2021 Trading Update29.7.2021 08:30:00 CEST | Press release

Capelle aan den Ijssel, The Netherlands 29 July 2021 - GeoJunxion significantly increases order intake and shows encouraging Q2 and 1H2021 YoY topline growth. Looking back at the first half of 2021 and more specifically at the second quarter, Covid-19 and its related measures are still proving to be a significant challenge for the global economy. However, the GeoJunxion team and our underlying business continued to show strong resilience and improved performance during Q2: Revenue during the past quarter has grown by 30% compared to the same quarter in 2020. For the first half of 2021, revenue increased by 20% compared to the same period last year. Thanks to an extraordinary Q2 performance, our order intake for the first half of 2021 doubled compared to the same period last year. We are continuously encouraged by the market response regarding our new premium location aware products and intelligence location services, which have resulted in the increased strength of our pipeline. It is

AB Klaipėdos nafta holds a Webinar regarding unaudited financial results for the six months of 202129.7.2021 08:00:00 CEST | Press release

On the 29th of July 2021 at 9:00 (EET) AB Klaipėdos nafta (hereinafter – the Company) holds a conference webinar for its shareholders, investors, mass media representatives and other stakeholders. The presentation is held in English. The webinar is hosted by KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė who introduces the Company’s financial results for the six months of 2021 and will answer the participant questions. Webinar presentation is enclosed. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276 Attachment KN_activity results for_2021_Q2

AB Klaipėdos nafta unaudited financial information regarding the six months of 202129.7.2021 07:55:00 CEST | Press release

AB Klaipėdos nafta (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and separate financial results for the six months ended 30 June 2021. Main financial indicators of the Group comparing 6 months of 2021 and 2020: Financial results for 6 months of 2021Change, compared to 6 months of 2020Adjusted results for 6 months of 2021 Change, compared to 6 months of 2020Revenue31.6 million EUR- 22.4%31.6 million EUR- 22.4%Net profit (loss)- 6.8 million EUR- 16.2 million EUR- 0.2 million EUR- 7.5 million EUREBITDA14.6 million EUR- 39.7%14.6 million EUR- 39.7% Main financial indicators of the Company comparing 6 months of 2021 and 2020: Financial results for 6 months of 2021Change, compared to 6 months of 2020Adjusted results for 6 months of 2021Change, compared to 6 months of 2020Revenue30.1 million EUR- 24.2%30.1 million EUR- 24.2%Net profit (loss)- 7.2 million EUR- 16.5 million EUR-0.7 million EUR- 7.9 million EUR EBITDA14.0 million EUR- 41.7%14.0 mi

NOMINATION OF CHIEF FINANCIAL OFFICER29.7.2021 07:30:00 CEST | Press release

NOMINATION OF CHIEF FINANCIAL OFFICER Amsterdam, the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces that the Supervisory Board has nominated Mike Kuehnel for appointment as Chief Financial Officer and member of the Management Board. Given Flow Traders’ ambitions and strategic growth agenda, the Supervisory Board has taken the decision to expand the Management Board from four to five members with the nomination of Mike Kuehnel for appointment as Chief Financial Officer. Through this new, dedicated Chief Financial Officer function, Mike will help to further shape Flow Traders’ strategy, develop organic and non-organic growth initiatives as well as intensify communications with key stakeholders. Mike Kuehnel will join Flow Traders on 1 August 2021 and all regulatory approvals have been received. Prior to joining Flow Traders, Mike gained over 20 years of investment banking and strategy consulting experience in the global financial market infrastructure space. Most recently, Mi

Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma29.7.2021 07:15:00 CEST | Press release

Basel, Switzerland, July 29, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Basilea’s tumor checkpoint controller, lisavanbulin, for the treatment of malignant glioma (brain cancer). This includes glioblastoma, the most common type of primary brain cancer and one of the most lethal types of cancer.1 Orphan Drug Designation qualifies the sponsor of the drug for various incentives, including longer regulatory market exclusivity. Dr. Marc Engelhardt, Chief Medical Officer, commented: “The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin. Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available. Lisavanbulin, as a targeted treatment, could be a useful new approach to expand the treatment options for patients with this devastating disease.” Basilea is currently conductin